FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Br J Pharmacol / Effect of selective IK,ACh inhibition by XAF-1407 in an equi...
British journal of pharmacology2020; 177(16); 3778-3794; doi: 10.1111/bph.15100

Effect of selective IK,ACh inhibition by XAF-1407 in an equine model of tachypacing-induced persistent atrial fibrillation.

Abstract: Inhibition of the G-protein gated ACh-activated inward rectifier potassium current, IK,ACh may be an effective atrial selective treatment strategy for atrial fibrillation (AF). Therefore, the anti-arrhythmic and electrophysiological properties of a novel putatively potent and highly specific IK,ACh inhibitor, XAF-1407 (3-methyl-1-[5-phenyl-4-[4-(2-pyrrolidin-1-ylethoxymethyl)-1-piperidyl]thieno[2,3-d]pyrimidin-6-yl]azetidin-3-ol), were characterised for the first time in vitro and investigated in horses with persistent AF. The pharmacological ion channel profile of XAF-1407 was investigated using cell lines expressing relevant ion channels. In addition, eleven horses were implanted with implantable cardioverter defibrillators enabling atrial tachypacing into self-sustained AF. The electrophysiological effects of XAF-1407 were investigated after serial cardioversions over a period of 1 month. Cardioversion success, drug-induced changes of atrial tissue refractoriness, and ventricular electrophysiology were assessed at baseline (day 0) and days 3, 5, 11, 17, and 29 after AF induction. XAF-1407 potently and selectively inhibited Kir 3.1/3.4 and Kir 3.4/3.4, underlying the IK,ACh current. XAF-1407 treatment in horses prolonged atrial effective refractory period as well as decreased atrial fibrillatory rate significantly (~20%) and successfully cardioverted AF, although with a decreasing efficacy over time. XAF-1407 shortened atrioventricular-nodal refractoriness, without effect on QRS duration. QTc prolongation (4%) within 15 min of drug infusion was observed, however, without any evidence of ventricular arrhythmia. XAF-1407 efficiently cardioverted sustained tachypacing-induced AF of short duration in horses without notable side effects. This supports IK,ACh inhibition as a potentially safe treatment of paroxysmal AF in horses, suggesting potential clinical value for other species including humans.
© 2020 The British Pharmacological Society.
Get Full Text
Publication Date: 2020-06-24 PubMed ID: 32436234PubMed Central: PMC7393200DOI: 10.1111/bph.15100Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research paper investigates the anti-arrhythmic and electrophysiological properties of a new compound, XAF-1407, in treating atrial fibrillation in horses. The study found that XAF-1407 efficiently treats sustained tachypacing-induced atrial fibrillation in horses with minimal side effects, suggesting potential use in other species including humans.

Explanation of the Research Paper

The research paper explains a study conducted on the properties of a new compound, XAF-1407 (3-methyl-1-[5-phenyl-4-[4-(2-pyrrolidin-1-ylethoxymethyl)-1-piperidyl]thieno[2,3-d]pyrimidin-6-yl]azetidin-3-ol), especially its inhibitory effect on specific ion channels involved in atrial fibrillation.

  • The first section of the research covers the investigation into the pharmacological ion channel profile of XAF-1407. The research team used cell lines displaying the relevant ion channels to test the effectiveness of the compound in inhibiting these channels.
  • The study then applies this understanding to practical experiments involving eleven horses. The horses are implanted with cardioverter defibrillators which are used to induce atrial fibrillation. The effect of XAF-1407 is then tested in these horses over a one-month period.
  • The results of these tests revealed that XAF-1407 has the ability to inhibit certain channels — specifically K 3.1/3.4 and K 3.4/3.4 which underlay the IK,ACh current — effectively. Treatment with XAF-1407 resulted in slowing down the atrial fibrillatory rate and led to successful cardioversion — the process of restoring the heart’s normal rhythm.
  • The compound was also found to cause minor QTc prolongation (an extension of the electrical recovery phase of the heart) within 15 minutes of drug infusion, but this observation did not result in any ventricular arrhythmia, suggesting the safety of the drug.

Significance of the Findings

These findings are significant as they suggest XAF-1407 as a potential treatment for atrial fibrillation. Specifically, the findings imply:

  • The ability of XAF-1407 to efficiently treat atrial fibrillation induced by tachypacing (rapid heartbeat) in horses. There were minimal side effects detected during the study period.
  • The study also suggests the potential of the compound for use in treating paroxysmal atrial fibrillation in horses, and implies potential clinical value in treating the condition in other species, including humans.

Cite This Article

APA
Fenner MF, Carstensen H, Dalgas Nissen S, Melis Hesselkilde E, Scott Lunddahl C, Adler Hess Jensen M, Loft-Andersen AV, Sattler SM, Platonov P, El-Haou S, Jackson C, Tang R, Kirby R, Ford J, Schotten U, Milnes J, Svane Sørensen U, Jespersen T, Buhl R. (2020). Effect of selective IK,ACh inhibition by XAF-1407 in an equine model of tachypacing-induced persistent atrial fibrillation. Br J Pharmacol, 177(16), 3778-3794. https://doi.org/10.1111/bph.15100

Publication

British journal of pharmacology
ISSN: 1476-5381
NlmUniqueID: 7502536
Country: England
Language: English
Volume: 177
Issue: 16
Pages: 3778-3794

Researcher Affiliations

Fenner, Merle Friederike
  • Department of Veterinary Clinical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Taastrup, Denmark.
Carstensen, Helena
  • Department of Veterinary Clinical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Taastrup, Denmark.
Dalgas Nissen, Sarah
  • Department of Veterinary Clinical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Taastrup, Denmark.
Melis Hesselkilde, Eva
  • Department of Veterinary Clinical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Taastrup, Denmark.
Scott Lunddahl, Christine
  • Department of Veterinary Clinical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Taastrup, Denmark.
Adler Hess Jensen, Maja
  • Department of Veterinary Clinical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Taastrup, Denmark.
Loft-Andersen, Ameli Victoria
  • Department of Veterinary Clinical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Taastrup, Denmark.
Sattler, Stefan Michael
  • Department of Cardiology, The Heart Centre, Copenhagen University Hospital, Copenhagen, Denmark.
  • Department of Medicine I, University Hospital Munich, Campus Grosshadern, Ludwig-Maximilians University Munich (LMU), Munich, Germany.
Platonov, Pyotr
  • Arrhythmia Clinic, Skåne University Hospital and Department of Cardiology, Clinical Sciences, Lund University, Lund, Sweden.
El-Haou, Said
  • Xention Ltd., Newmarket, UK.
Jackson, Claire
  • Xention Ltd., Newmarket, UK.
Tang, Raymond
  • Xention Ltd., Newmarket, UK.
Kirby, Robert
  • Xention Ltd., Newmarket, UK.
Ford, John
  • Xention Ltd., Newmarket, UK.
Schotten, Ulrich
  • Department of Physiology, Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands.
Milnes, James
  • Xention Ltd., Newmarket, UK.
Svane Sørensen, Ulrik
  • Acesion A/S, Copenhagen, Denmark.
Jespersen, Thomas
  • Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Buhl, Rikke
  • Department of Veterinary Clinical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Taastrup, Denmark.

MeSH Terms

  • Animals
  • Anti-Arrhythmia Agents / pharmacology
  • Atrial Fibrillation / drug therapy
  • Heart Atria
  • Horses
  • Potassium

Grant Funding

  • Oda og Hans Svenningsens Fond
  • Kirsten og Freddy Johansens Fond
  • The Kustos Foundation of 1881
  • DFF-7017-00050 / The Independent Research Fund Denmark
  • 675351 / European Union Horizon 2020 MSCA ITN

Conflict of Interest Statement

The authors S.E.‐H., C.J., R.T., R.K., J.F., and J.M. were employees of former Xention Ltd but no longer have financial interest in the experimental compound (XAF‐1407) mentioned within this article. The experimental compound XAF‐1407 was provided free of charge. The other authors (M.F.F., H.C., S.D.N., E.Z.H., C.L., M.A.J., A.V.L.‐A., S.M.S., P.G.P., U.S., U.S.S., T.J., and R.B.) report no conflicts of interest.

References

This article includes 55 references
  1. Alexander SPH, Fabbro D, Kelly E, Mathie A, Peters JA, Veale EL, CGTP Collaborators. THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Enzymes. British Journal of Pharmacology 176, S297–S396.
    doi: 10.1111/bph.14752pmc: PMC6844577pubmed: 31710714google scholar: lookup
  2. Alexander SPH, Mathie A, Peters JA, Veale EL, Striessnig J, Kelly E, Zhu M. The Concise Guide to PHARMACOLOGY 2019/20: Ion channels. British Journal of Pharmacology 176(S1), S142–S228.
    doi: 10.1111/bph.14749pmc: PMC6844578pubmed: 31710715google scholar: lookup
  3. Allessie M, Ausma J, Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovascular Research 54(2), 230–246.
    doi: 10.1016/S0008-6363(02)00258-4pubmed: 12062329google scholar: lookup
  4. Brundel BJJM, Van Gelder IC, Henning RH, Tuinenburg AE, Wietses M, Grandjean JG, Crijns HJ. Alterations in potassium channel gene expression in atria of patients with persistent and paroxysmal atrial fibrillation: Differential regulation of protein and mRNA levels for K+ channels. Journal of the American College of Cardiology 37(3), 926–932.
    doi: 10.1016/S0735-1097(00)01195-5pubmed: 11693772google scholar: lookup
  5. Carstensen H, Hesselkilde EZ, Fenner M, Loft‐Andersen AV, Flethøj M, Kanters JK, Buhl R. Time‐dependent antiarrhythmic effects of flecainide on induced atrial fibrillation in horses. Journal of Veterinary Internal Medicine 32(5), 1708–1717.
    doi: 10.1111/jvim.15287pmc: PMC6189357pubmed: 30133839google scholar: lookup
  6. Carstensen H, Kjær L, Haugaard MM, Flethøj M, Hesselkilde EZ, Kanters JK, Jespersen T. Antiarrhythmic effects of combining dofetilide and ranolazine in a model of acutely induced atrial fibrillation in horses. Journal of Cardiovascular Pharmacology 71(1), 1–35.
    doi: 10.1097/FJC.0000000000000541pmc: PMC5768216pubmed: 29068807google scholar: lookup
  7. Curtis MJ, Alexander S, Cirino G, Docherty JR, George CH, Giembycz MA, Ahluwalia A. Experimental design and analysis and their reporting II: Updated and simplified guidance for authors and peer reviewers. British Journal of Pharmacology 175(7), 987–993.
    doi: 10.1111/bph.14153pmc: PMC5843711pubmed: 29520785google scholar: lookup
  8. De Clercq D, Van Loon G, Tavernier R, Duchateau L, Deprez P. Atrial and ventricular electrical and contractile remodeling and reverse remodeling owing to short‐term pacing‐induced atrial fibrillation in horses. Journal of Veterinary Internal Medicine 22(6), 1353–1359.
    doi: 10.1111/j.1939-1676.2008.0202.xpubmed: 19000247google scholar: lookup
  9. Diness JG, Skibsbye L, Simó‐Vicens R, Santos JL, Lundegaard P, Citerni C, Bentzen BH. Termination of vernakalant‐resistant atrial fibrillation by inhibition of small‐conductance Ca2+‐activated K+ channels in pigs. Circulation. Arrhythmia and Electrophysiology 10(10), 1–13.
    doi: 10.1161/CIRCEP.117.005125pmc: PMC5647113pubmed: 29018164google scholar: lookup
  10. Diness JG, Sørensen US, Nissen JD, Al‐Shahib B, Jespersen T, Grunnet M, Hansen RS. Inhibition of small‐conductance Ca2+‐activated K+ channels terminates and protects against atrial fibrillation. Circulation. Arrhythmia and Electrophysiology 3(4), 380–390.
    doi: 10.1161/CIRCEP.110.957407pubmed: 20562443google scholar: lookup
  11. Dobrev D, Friedrich A, Voigt N, Jost N, Wettwer E, Christ T, Ravens U. The G protein‐gated potassium current IK,ACh is constitutively active in patients with chronic atrial fibrillation. Circulation 112(24), 3697–3706.
    doi: 10.1161/CIRCULATIONAHA.105.575332pubmed: 16330682google scholar: lookup
  12. Dobrev D, Graf E, Wettwer E, Himmel HM, Hála O, Doerfel C, Ravens U. Molecular Basis of Downregulation of G‐Protein–Coupled Inward Rectifying K+Current (IK,ACh) in Chronic Human Atrial Fibrillation. Circulation 104(21), 2551–2557.
    doi: 10.1161/hc4601.099466pubmed: 11714649google scholar: lookup
  13. Dobrev D, Wettwer E, Kortner A, Knaut M, Schuler S, Ravens U. Human inward rectifier potassium channels in chronic and postoperative atrial fibrillation. Cardiovascular Research 54(2), 397–404.
    doi: 10.1016/s0008-6363(01)00555-7pubmed: 12062344google scholar: lookup
  14. Drici MD, Diochot S, Terrenoire C, Romey G, Lazdunski M. The bee venom peptide tertiapin underlines the role of I KACh in acetylcholine‐induced atrioventricular blocks. British Journal of Pharmacology 131(3), 569–577.
    doi: 10.1038/sj.bjp.0703611pmc: PMC1572365pubmed: 11015309google scholar: lookup
  15. El‐Haou S, Ford JW, Milnes JT. Novel K+ channel targets in atrial fibrillation drug development—Where are we?. Journal of Cardiovascular Pharmacology 66(5), 412–431.
    doi: 10.1097/FJC.0000000000000277pubmed: 25978691google scholar: lookup
  16. Harding SD, Sharman JL, Faccenda E, Southan C, Pawson AJ, Ireland S, NC‐IUPHAR. The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: Updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY. Nucleic Acids Research 46(D1), D1091–D1106.
    doi: 10.1093/nar/gkx1121pmc: PMC5753190pubmed: 29149325google scholar: lookup
  17. Hashimoto N, Yamashita T, Tsuruzoe N. Tertiapin, a selective IKACh blocker, terminates atrial fibrillation with selective atrial effective refractory period prolongation. Pharmacological Research 54(2), 136–141.
    doi: 10.1016/j.phrs.2006.03.021pubmed: 16725344google scholar: lookup
  18. Hashimoto N, Yamashita T, Tsuruzoe N. Characterization of in vivo and in vitro electrophysiological and antiarrhythmic effects of a novel IKACh blocker, NIP‐151: A comparison with an IKr‐blocker dofetilide. Journal of Cardiovascular Pharmacology 51(2), 162–169.
    doi: 10.1097/FJC.0b013e31815e854cpubmed: 18287884google scholar: lookup
  19. Haugaard M, Hesselkilde E, Pehrson S, Carstensen H, Flethøj M, Præstegaard K, Jespersen T. Pharmacologic inhibition of small‐conductance calcium‐activated potassium (SK) channels by NS8593 reveals atrial antiarrhythmic potential in horses. Heart Rhythm 12(4), 825–835.
    doi: 10.1016/j.hrthm.2014.12.028pubmed: 25542425google scholar: lookup
  20. Haugaard M, Pehrson S, Carstensen H, Flethøj M, Hesselkilde E, Præstegaard K, Buhl R. Antiarrhythmic and electrophysiologic effects of flecainide on acutely induced atrial fibrillation in healthy horses. Journal of Veterinary Internal Medicine 29(1), 339–347.
    doi: 10.1111/jvim.12496pmc: PMC4858114pubmed: 25328012google scholar: lookup
  21. Heijman J, Ghezelbash S, Dobrev D. Investigational antiarrhythmic agents: promising drugs in early clinical development. Expert Opinion on Investigational Drugs 26(8), 897–907.
    doi: 10.1080/13543784.2017.1353601pmc: PMC6324729pubmed: 28691539google scholar: lookup
  22. Hesselkilde EZ, Carstensen H, Flethøj M, Fenner M, Kruse DD, Sattler SM, Buhl R. Longitudinal study of electrical, functional and structural remodelling in an equine model of atrial fibrillation. BMC Cardiovascular Disorders 19(1), 1–12.
    doi: 10.1186/s12872-019-1210-4pmc: PMC6805623pubmed: 31638896google scholar: lookup
  23. Hesselkilde EZ, Carstensen H, Haugaard MM, Carlson J, Pehrson S, Jespersen T, Platonov PG. Effect of flecainide on atrial fibrillatory rate in a large animal model with induced atrial fibrillation. BMC Cardiovascular Disorders 17(1), 4–9.
    doi: 10.1186/s12872-017-0720-1pmc: PMC5723027pubmed: 29221440google scholar: lookup
  24. Humphries ESA, Dart C. Neuronal and cardiovascular potassium channels as therapeutic drug targets: Promise and pitfalls. Journal of Biomolecular Screening 20(9), 1055–1073.
    doi: 10.1177/1087057115601677pmc: PMC4576507pubmed: 26303307google scholar: lookup
  25. Husser D, Stridh M, Sornmo L, Olsson SB, Bollmann A. Frequency analysis of atrial fibrillation from the surface electrocardiogram. Indian Pacing and Electrophysiology Journal 4(3), 122–136.
    pmc: PMC1501079pubmed: 16943980
  26. Kaese S, Verheule S. Cardiac electrophysiology in mice: A matter of size. Frontiers in Physiology 3 SEP (September), 1–19.
    doi: 10.3389/fphys.2012.00345pmc: PMC3433738pubmed: 22973235google scholar: lookup
  27. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG. Animal research: Reporting in vivo experiments: The ARRIVE guidelines. British Journal of Pharmacology 160, 1577–1579.
    pmc: PMC2936830pubmed: 20649561
  28. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Zeppenfeld K. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal 37(38), 2893–2962.
    doi: 10.1093/eurheartj/ehw210pubmed: 27567408google scholar: lookup
  29. Kovoor P, Wickman K, Maguire CT, Pu W, Gehrmann J, Berul CI, Clapham DE. Evaluation of the role of IKACh in atrial fibrillation using a mouse knockout model. Journal of the American College of Cardiology 37(8), 2136–2143.
    doi: 10.1016/S0735-1097(01)01304-3pubmed: 11419900google scholar: lookup
  30. Makary S, Voigt N, Maguy A, Wakili R, Nishida K, Harada M, Nattel S. Differential protein kinase C isoform regulation and increased constitutive activity of acetylcholine‐regulated potassium channels in atrial remodeling. Circulation Research 109(9), 1031–1043.
    doi: 10.1161/CIRCRESAHA.111.253120pubmed: 21903936google scholar: lookup
  31. Milnes JT, Madge DJ, Ford JW. New pharmacological approaches to atrial fibrillation. Drug Discovery Today 17(13–14), 654–659.
    doi: 10.1016/j.drudis.2012.02.007pubmed: 22370250google scholar: lookup
  32. Pedersen PJ, Karlsson M, Flethøj M, Trachsel DS, Kanters JK, Klaerke DA, Buhl R. Differences in the electrocardiographic QT interval of various breeds of athletic horses during rest and exercise. Journal of Veterinary Cardiology 18(3), 255–264.
    doi: 10.1016/j.jvc.2016.02.002pubmed: 27068842google scholar: lookup
  33. Platonov PG, Corino VDA, Seifert M, Holmqvist F, Sörnmo L. Atrial fibrillatory rate in the clinical context: Natural course and prediction of intervention outcome. Europace 16, iv110–iv119.
    doi: 10.1093/europace/euu249pubmed: 25362161google scholar: lookup
  34. Podd SJ, Freemantle N, Furniss SS, Sulke N. First clinical trial of specific IKACh blocker shows no reduction in atrial fibrillation burden in patients with paroxysmal atrial fibrillation: Pacemaker assessment of BMS 914392 in patients with paroxysmal atrial fibrillation. Europace 18(3), 340–346.
    doi: 10.1093/europace/euv263pubmed: 26462707google scholar: lookup
  35. Qi XY, Diness JG, Brundel BJJM, Zhou XB, Naud P, Wu CT, Nattel S. Role of small‐conductance calcium‐activated potassium channels in atrial electrophysiology and fibrillation in the dog. Circulation 129(4), 430–440.
    doi: 10.1161/CIRCULATIONAHA.113.003019pubmed: 24190961google scholar: lookup
  36. Ravens U. Antiarrhythmic therapy in atrial fibrillation. Pharmacology & Therapeutics 128(1), 129–145.
    doi: 10.1016/j.pharmthera.2010.06.004pubmed: 20624425google scholar: lookup
  37. Ravens U, Poulet C, Wettwer E, Knaut M. Atrial selectivity of antiarrhythmic drugs. Journal of Physiology 591(17), 4087–4097.
    doi: 10.1113/jphysiol.2013.256115pmc: PMC3779104pubmed: 23732646google scholar: lookup
  38. Reef VB, Bonagura J, Buhl R, Mcgurrin MKJ, Schwarzwald CC, van Loon G, Young LE. Recommendations for management of equine athletes with cardiovascular abnormalities. Journal of Veterinary Internal Medicine 28(3), 749–761.
    doi: 10.1111/jvim.12340pmc: PMC4895474pubmed: 24628586google scholar: lookup
  39. Schotten U, Duytschaever M, Ausma J, Eijsbouts S, Neuberger HR, Allessie M. Electrical and contractile remodeling during the first days of atrial fibrillation go hand in hand. Circulation 107(10), 1433–1439.
    doi: 10.1161/01.CIR.0000055314.10801.4Fpubmed: 12642366google scholar: lookup
  40. Sharma D, Li G, Xu G, Liu Y, Xu Y. Atrial remodeling in atrial fibrillation and some related microRNAs. Cardiology 120(2), 111–121.
    doi: 10.1159/000334434pubmed: 22179059google scholar: lookup
  41. Shen MJ, Zipes DP. Role of the autonomic nervous system in modulating cardiac arrhythmias. Circulation Research 114(6), 1004–1021.
    doi: 10.1161/CIRCRESAHA.113.302549pubmed: 24625726google scholar: lookup
  42. Skibsbye L, Ravens U. Mechanism of proarrhythmic effects of potassium channel blockers. Cardiac Electrophysiology Clinics 8(2), 395–410.
    doi: 10.1016/j.ccep.2016.02.004pubmed: 27261830google scholar: lookup
  43. Stridh M, Sörnmo L. Spatiotemporal QRST cancellation techniques for analysis of atrial fibrillation. IEEE Transactions on Biomedical Engineering 48(1), 105–111.
    doi: 10.1109/10.900266pubmed: 11235581google scholar: lookup
  44. Van Hunnik A, Lau DH, Zeemering S, Kuiper M, Verheule S, Schotten U. Antiarrhythmic effect of vernakalant in electrically remodeled goat atria is caused by slowing of conduction and prolongation of postrepolarization refractoriness. Heart Rhythm 13(4), 964–972.
    doi: 10.1016/j.hrthm.2015.12.009pubmed: 26681610google scholar: lookup
  45. Van Loon G, Duytschaever M, Tavernier R, Fonteyne W, Jordaens L, Deprez P. An equine model of chronic atrial fibrillation: Methodology. The Veterinary Journal 164(2), 142–150.
    doi: 10.1053/tvjl.2001.0668pubmed: 12359469google scholar: lookup
  46. Verheyen T, Decloedt A, De Clercq D, Deprez P, Sys SU, Van Loon G. Electrocardiography in horses—Part 2: How to read the equine ECG. Vlaams Diergeneeskundig Tijdschrift 79(5), 337–344.
  47. Voigt N, Abu‐Taha I, Heijman J, Dobrev D. Constitutive activity of the acetylcholine‐activated potassium current IK,ACh in cardiomyocytes In Advances in pharmacology (1st ed., Vol. 70). Elsevier Inc. .
    doi: 10.1016/B978-0-12-417197-8.00013-4pubmed: 24931203google scholar: lookup
  48. Voigt N, Dobrev D. Atrial‐selective potassium channel blockers. Cardiac Electrophysiology Clinics 8(2), 411–421.
    doi: 10.1016/j.ccep.2016.02.005pubmed: 27261831google scholar: lookup
  49. Voigt N, Friedrich A, Bock M, Wettwer E, Christ T, Knaut M, Dobrev D. Differential phosphorylation‐dependent regulation of constitutively active and muscarinic receptor‐activated IK,ACh channels in patients with chronic atrial fibrillation. Cardiovascular Research 74(3), 426–437.
    doi: 10.1016/j.cardiores.2007.02.009pubmed: 17362895google scholar: lookup
  50. Waks JW, Zimetbaum P. Antiarrhythmic drug therapy for rhythm control in atrial fibrillation. Journal of Cardiovascular Pharmacology and Therapeutics 22(1), 3–19.
    doi: 10.1177/1074248416651722pubmed: 27260643google scholar: lookup
  51. Walfridsson H, Anfinsen OG, Berggren A, Frison L, Jensen S, Linhardt G, Carlsson L. Is the acetylcholine‐regulated inwardly rectifying potassium current a viable antiarrhythmic target? Translational discrepancies of AZD2927 and A7071 in dogs and humans. Europace 17(3), 473–482.
    doi: 10.1093/europace/euu192pubmed: 25082948google scholar: lookup
  52. Wang X, Liang B, Skibsbye L, Olesen SP, Grunnet M, Jespersen T. GIRK channel activation via adenosine or muscarinic receptors has similar effects on rat atrial electrophysiology. Journal of Cardiovascular Pharmacology 62(2), 192–198.
    doi: 10.1097/FJC.0b013e3182965221pubmed: 23609329google scholar: lookup
  53. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 92(7), 1954–1968.
    doi: 10.1161/01.CIR.92.7.1954pubmed: 7671380google scholar: lookup
  54. Yamada M, Inanobe A, Kurachi Y. G protein regulation of potassium ion channels. Pharmacological Reviews 50(4), 723–757.
    pubmed: 9860808
  55. Yang Y, Yang Y, Liang B, Liu J, Li J, Grunnet M, Chen YH. Identification of a Kir3.4 mutation in congenital long QT syndrome. American Journal of Human Genetics 86(6), 872–880.
    doi: 10.1016/j.ajhg.2010.04.017pmc: PMC3032079pubmed: 20560207google scholar: lookup
Subscribe to our newsletter
Join 99,034 horse owners like you who receive our email updates on horse health and nutrition.